CAMBRIDGE, Mass., May 22, 2024
/PRNewswire/ -- Nona Biosciences, a global biotechnology company
providing a total solution from "Idea to IND" (I to
ITM), ranging from target validation and antibody
discovery through preclinical research, announced today that it has
entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq:
AZN) for preclinical monoclonal antibodies that will be used to
create targeted therapies in oncology.
Under the terms of the agreement, Nona Biosciences shall receive
US$19 million upon completion of the
transaction. Nona is eligible to receive an additional US$10 million in potential near-term milestone
payments and up to US$575 million
upon achieving specified development, regulatory, and commercial
milestones, as well as tiered royalty payments on net sales. In
addition, Nona is eligible to receive payments for the option
programs should AstraZeneca exercise these options.
"We are delighted to announce this agreement with AstraZeneca,
global leaders in developing tumor targeted therapies, to maximize
the potential of our novel antibodies," said Jingsong Wang, M.D., Ph.D., Chairman of Nona
Biosciences. "This agreement further validates our leading antibody
discovery platform, and we look forward to seeing our antibodies
developed into potential new medicines for cancer patients."
Puja Sapra, Senior Vice
President, Tumour Targeted Delivery, Oncology R&D, AstraZeneca,
said: "The global license agreement with Nona Biosciences is an
exciting opportunity to further develop these antibodies derived
from Nona's innovative biologics discovery engine into novel tumor
targeted therapies using AstraZeneca's industry-leading
capabilities."
About Nona Biosciences
Nona Biosciences (a wholly-owned subsidiary of HBM Holdings
Limited, HKEX: 02142) is a global biotechnology company committed
to cutting-edge technology innovation and provides a total solution
from "Idea to IND" (I to ITM), ranging from target
validation and antibody discovery through preclinical research. The
integrated antibody discovery services range from antigen
preparation, animal immunization, highly robust antibody screening,
to antibody lead generation and engineering, developability
assessment and pharmacological evaluation, leveraging advantages of
Harbour Mice® technology and the experienced therapeutic
antibody discovery team.
Harbour Mice® generate fully human monoclonal
antibodies in a traditional two heavy and two light chain (H2L2)
format, and a heavy chain only (HCAb) format. Integrating Harbour
Mice® with highly robust antibody screening platforms,
Nona Biosciences is focused on driving global inventions of
transformative next-generation drugs. For more information, please
visit www.nonabio.com and follow us on LinkedIn.
View original
content:https://www.prnewswire.com/news-releases/nona-biosciences-announces-global-license-and-option-agreement-with-astrazeneca-for-monoclonal-antibody-to-be-developed-into-novel-tumor-targeted-therapies-302153513.html
SOURCE Nona Biosciences